188. Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.Selective Loss of PARG Restores PARylation and Counteracts PARPInhibitor-Mediated Synthetic Lethality.Gogola E(1), Duarte AA(1), de Ruiter JR(2), Wiegant WW(3), Schmid JA(4), deBruijn R(2), James DI(5), Guerrero Llobet S(6), Vis DJ(7), Annunziato S(1), vanden Broek B(8), Barazas M(1), Kersbergen A(9), van de Ven M(10), Tarsounas M(11),Ogilvie DJ(5), van Vugt M(6), Wessels LFA(7), Bartkova J(12), Gromova I(13),Andújar-Sánchez M(14), Bartek J(12), Lopes M(4), van Attikum H(3), Borst P(9),Jonkers J(15), Rottenberg S(16).Author information: (1)Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam1066CX, the Netherlands.(2)Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam1066CX, the Netherlands; Division of Molecular Carcinogenesis, The NetherlandsCancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands,Oncode Institute, Amsterdam 1066CX, the Netherlands.(3)Department of Human Genetics, Leiden University Medical Center, Leiden 2333ZC, the Netherlands.(4)Institute of Molecular Cancer Research, University of Zurich, Zurich CH-8057, Switzerland.(5)Drug Discovery Unit, Cancer Research UK Manchester Institute, University ofManchester, Manchester M20 4BX, UK.(6)Department of Medical Oncology, University Medical Center Groningen,University of Groningen, Groningen 9723GZ, the Netherlands.(7)Division of Molecular Carcinogenesis, The Netherlands Cancer Institute,Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute,Amsterdam 1066CX, the Netherlands.(8)Division of Cell Biology and BioImaging Facility, The Netherlands CancerInstitute, Amsterdam 1066CX, the Netherlands.(9)Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam1066CX, the Netherlands.(10)Mouse Clinic for Cancer and Aging (MCCA), Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands.(11)CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford,Oxford OX3 7DQ, UK.(12)Danish Cancer Society Research Center, Copenhagen 2100, Denmark; KarolinskaInstitute, Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Science for Life Laboratory, Stockholm 171 77, Sweden.(13)Danish Cancer Society Research Center, Copenhagen 2100, Denmark.(14)Pathology Department, Complejo Hospt. Univ. Insular Materno Infantil, LasPalmas, Gran Canaria, Spain.(15)Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam1066CX, the Netherlands. Electronic address: j.jonkers@nki.nl.(16)Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Institute of Animal Pathology, Vetsuisse Faculty,University of Bern, Bern 3012, Switzerland. Electronic address:sven.rottenberg@vetsuisse.unibe.ch.Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered theclinic for the treatment of homologous recombination (HR)-deficient cancers.Despite the success of this approach, drug resistance is a clinical hurdle, andwe poorly understand how cancer cells escape the deadly effects of PARPi without restoring the HR pathway. By combining genetic screens with multi-omics analysis of matched PARPi-sensitive and -resistant Brca2-mutated mouse mammary tumors, we identified loss of PAR glycohydrolase (PARG) as a major resistance mechanism. We also found the presence of PARG-negative clones in a subset of human serousovarian and triple-negative breast cancers. PARG depletion restores PAR formationand partially rescues PARP1 signaling. Importantly, PARG inactivation exposesvulnerabilities that can be exploited therapeutically.Copyright © 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.ccell.2018.05.008 PMID: 29894693 